H

ello, everyone, and how are you this fine morning? The middle of the week has arrived, as you may know, so why not celebrate with a delicious cup of stimulation? After all, you made is this far, which is a likely sign of surviving another few days. And, of course, no prescription is required, which is a good thing. And while you drink up, you can peruse some of the tidbits we have assembled to help you start the day. Hope you conquer the world and, as always, do keep in touch …

Merck (MRK) plans to build a new facility in Dublin on the site of its former women’s health care products business, and create 350 jobs, the Irish Times tells us. The drug maker, which wants to ramp up global manufacturing capacity for its Keytruda cancer therapy, expects the new facility to be operational in 2021 and fully certified by 2022. The company had put the facility on the market last year after it transferred the long-standing women’s health products business from the site to the Netherlands.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy